A Phase IIb Randomised Clinical Trial of the Tolerability, Safety and Efficacy of Adjuvant Docetaxel-Zoledronic Acid After Prostatectomy for High-risk Early Prostate Cancer (AD-ZAP).

Trial Profile

A Phase IIb Randomised Clinical Trial of the Tolerability, Safety and Efficacy of Adjuvant Docetaxel-Zoledronic Acid After Prostatectomy for High-risk Early Prostate Cancer (AD-ZAP).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2010

At a glance

  • Drugs Docetaxel; Zoledronic acid
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AD-ZAP
  • Sponsors Novartis
  • Most Recent Events

    • 20 Apr 2010 Actual end date (Nov 2006) and actual number of patients (1) added as reported by ClinicalTrials.gov.
    • 07 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top